ClinVar Miner

Submissions for variant NM_000138.5(FBN1):c.1837+5G>A

dbSNP: rs1445085747
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 9
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Invitae RCV000631930 SCV000753033 pathogenic Marfan syndrome; Familial thoracic aortic aneurysm and aortic dissection 2023-08-08 criteria provided, single submitter clinical testing For these reasons, this variant has been classified as Pathogenic. Variants that disrupt the consensus splice site are a relatively common cause of aberrant splicing (PMID: 17576681, 9536098). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may create or strengthen a splice site. ClinVar contains an entry for this variant (Variation ID: 527158). This variant has been observed in individuals with Marfan syndrome (PMID: 10612827, 14695540, 19839986, 28642162). This variant is present in population databases (no rsID available, gnomAD 0.003%). This sequence change falls in intron 15 of the FBN1 gene. It does not directly change the encoded amino acid sequence of the FBN1 protein. It affects a nucleotide within the consensus splice site.
GeneDx RCV001536170 SCV001752890 likely pathogenic not provided 2023-03-15 criteria provided, single submitter clinical testing Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis predicts this variant may weaken or destroy the splice donor site in intron 15 and may cause abnormal gene splicing; however, in the absence of functional mRNA studies, the physiological consequence of this variant cannot be precisely determined; This variant is associated with the following publications: (PMID: 9399842, 14695540, 19839986, 28642162, 10612827, 35058154)
Centre of Medical Genetics, University of Antwerp RCV000663500 SCV002025515 likely pathogenic Marfan syndrome 2021-03-01 criteria provided, single submitter research PM2, PS1, PP4
Ambry Genetics RCV002413803 SCV002715038 likely pathogenic Familial thoracic aortic aneurysm and aortic dissection 2021-01-14 criteria provided, single submitter clinical testing The c.1837+5G>A intronic variant results from a G to A substitution 5 nucleotides after coding exon 14 in the FBN1 gene. This nucleotide position is well conserved in available vertebrate species. This alteration has been detected in one individual with a clinical diagnosis of Marfan syndrome as well as in two individuals with ectopia lentis, one of whom also had skeletal manifestations (Biggin A et al. Hum. Mutat., 2004 Jan;23:99; Hung CC et al. Ann. Hum. Genet., 2009 Nov;73:559-67; Overwater E et al. Eur J Med Genet, 2017 Sep;60:465-473). In silico splice site analysis predicts that this alteration may weaken the native splice donor site and will result in the creation or strengthening of a novel splice donor site. Based on the majority of available evidence to date, this variant is likely to be pathogenic.
Fulgent Genetics, Fulgent Genetics RCV002507064 SCV002805506 likely pathogenic Ectopia lentis 1, isolated, autosomal dominant; Marfan syndrome; MASS syndrome; Stiff skin syndrome; Weill-Marchesani syndrome 2, dominant; Acromicric dysplasia; Geleophysic dysplasia 2; Progeroid and marfanoid aspect-lipodystrophy syndrome 2021-07-03 criteria provided, single submitter clinical testing
Women's Health and Genetics/Laboratory Corporation of America, LabCorp RCV003117440 SCV003800652 pathogenic Marfan Syndrome/Loeys-Dietz Syndrome/Familial Thoracic Aortic Aneurysms and Dissections 2023-01-23 criteria provided, single submitter clinical testing Variant summary: FBN1 c.1837+5G>A alters a nucleotide located close to a canonical splice site and therefore could affect mRNA splicing, leading to a significantly altered protein sequence. Several computational tools predict a significant impact on normal splicing: One predict the variant abolishes a 5' splicing donor site. Two predict the variant weakens a 5' donor site. However, these predictions have yet to be confirmed by functional studies. The variant allele was found at a frequency of 4e-06 in 251316 control chromosomes. c.1837+5G>A has been reported in the literature in multiple individuals affected with Marfan Syndrome (Franken_2016, Franken_2017) and other related phenotypes: Dural Ectasia (Hung_2009) and Ectopia Lentis (Biggin_2004, Overwater_2017). These data indicate that the variant is very likely to be associated with disease. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. Six clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation and classified as VUS (n=1), Likely Pathogenic (n=4) and Pathogenic (n=1). Based on the evidence outlined above, the variant was classified as pathogenic.
Color Diagnostics, LLC DBA Color Health RCV002413803 SCV004357457 likely pathogenic Familial thoracic aortic aneurysm and aortic dissection 2023-02-01 criteria provided, single submitter clinical testing This variant causes a G to A nucleotide substitution at the +5 position of intron 15 of the FBN1 gene. Splice site prediction tools predict that this variant may have a significant impact on RNA splicing. To our knowledge, RNA studies have not been reported for this variant. This variant has been reported in two individuals affected with Marfan syndrome and in an individual suspected of having Marfan syndrome (PMID: 9399842, 19839986, 25652356). This variant has also been reported in another two individuals affected with ectopia lentis (PMID: 14695540, 28642162). This variant has been identified in 1/251316 chromosomes in the general population by the Genome Aggregation Database (gnomAD). Based on the available evidence, this variant is classified as Likely Pathogenic.
All of Us Research Program, National Institutes of Health RCV000663500 SCV004821092 likely pathogenic Marfan syndrome 2023-04-28 criteria provided, single submitter clinical testing This variant causes a G to A nucleotide substitution at the +5 position of intron 15 of the FBN1 gene. Splice site prediction tools predict that this variant may have a significant impact on RNA splicing. To our knowledge, RNA studies have not been reported for this variant. This variant has been reported in two individuals affected with Marfan syndrome and in an individual suspected of having Marfan syndrome (PMID: 9399842, 19839986, 25652356). This variant has also been reported in another two individuals affected with ectopia lentis (PMID: 14695540, 28642162). This variant has been identified in 1/251316 chromosomes in the general population by the Genome Aggregation Database (gnomAD). Based on the available evidence, this variant is classified as Likely Pathogenic.
Center for Medical Genetics Ghent, University of Ghent RCV000663500 SCV000786799 uncertain significance Marfan syndrome 2017-11-07 no assertion criteria provided clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.